-
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
Izquierdo et al., 2022, Cancer Discov. DOI: 10.1158/2159-8290.CD-20-0930 Mitogen-activated protein kinase (MAPK) pathway alterations are commonly found in childhood cancer, particularly brain tumors, and especially low- and high-grade gliomas. Although targeted agents against the MAPK pathway (inhibitors targeting BRAF – vemurafenib, dabrafenib and MEK – trametinib, selumetinib, cobimetinib) have become an important initial success story
-
Targeting the multifaceted BRAF in cancer: New directions
Toye et al., 2024. Oncotarget. DOI: 10.18632/oncotarget.28612. PMID: 39018217
-
Effective targeting of PDGFRA-altered high-grade glioma with Avapritinib
(Lisa Mayr et al., 2025. Cancer Cell. DOI: 10.1016/j.ccell.2025.02.018. PMID: 40086436) [Discussion] Recent collective sequencing efforts have identified several key molecular drivers of pediatric and young adult patients diagnosed with HGG or DMG. Among them, PDGFRA has emerged as a promising therapeutic target due to its frequent genomic alterations and its essential role in driving
-
Tumour Heterogeneity and Resistance to Cancer Therapies
Dagogo-Jack and Shaw, Nat Rev Clin Oncol 15, 81-94 (2018) One of the biggest challenges in precision oncology is the dynamic and multifaceted nature of tumour heterogeneity. Dagogo‑Jack and Shaw articulate how intra- and intertumoural heterogeneity drive resistance to targeted therapies, immunotherapies, and even cytotoxic agents.
-
Liquid Biopsy – Priming Agents Transiently Reduce the Clearance of Cell-Free DNA to Improve Liquid Biopsies
Martin-Alonso et al., 2024, Science 383, 274 During the course of my Master’s degree in Cancer Biology at Imperial College London, UK, one of the projects I have been working on was titled “Searching for oncogenic mutations in circulating tumor DNA (ctDNA) from gestational trophoblastic tumors (GTT)”. The rationale behind this project was to identify
-
A new genomic framework to categorize pediatric acute myeloid leukemia
Umeda et al., 2024, Nature Genetics. DOI: 10.1038/s41588-023-01640-3 Many pediatric-specific driver alterations are underrepresented in the current classification schemas. The study systemically categorized 887 pAML into 23 mutually distinct molecular categories. These included major entities covering 91.4% of the cohort, such as UBTF and BCL11B.
oncolojiin.com 